Article Sidebar
Views PDF: 352
EFFICACY, EFFECTIVENESS, SAFETY AND COST-EFFECTIVENESS OF BUDESONIDE/ GLYCOPYRROLATE/ FORMOTEROL FUMARATE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A SYSTEMATIC REVIEW
Main Article Content
Abstract
Background: The triple inhaled therapy budesonide/glycopyrrolate/formoterol fumarate (BGF) has the potential to increase adherence and efficacy in patients with chronic obstructive pulmonary disease (COPD). Objective: To systematically review the efficacy, effectiveness, safety, and cost-effectiveness of BGF in the treatment of COPD. Methods: The systematic review was conducted according to the guidance of PRISMA guidelines using 2 databases (Pubmed and Embase). Results: Of 16 included studies, 12/16 were RCTs (two large RCTs were ETHOS and KRONOS). BGF wherein budesonide dose of 160-μg and 320-μg improved lung function, symptoms and COPD exacerbation rate, regardless of history of COPD exacerbations. The safety profile of BGF was generally comparable to that of the comparison groups. BGF was cost-effective compared to other dual therapies such as LAMA/LABA or ICS/LABA. Conclusions: BGF was efficacious, well tolerated, cost-effective and could be a more appropriate treatment than the corresponding dual therapies and have potential compared to triple therapies for symptomatic patients with moderate to very severe COPD.
Article Details
Keywords
budesonide/glycopyrrolate/formoterol fumarate, chronic obstructive pulmonary disease.
References
2. World Health Organization. Global health estimates 2016: deaths by cause, age, sex, by country and by region 2000–2016 2018. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates (accessed May 8, 2023).
3. Koarai A, Yamada M, Ichikawa T, Fujino N, Kawayama T, Sugiura H. Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis. Respiratory Research 2021;22:183. https://doi.org/10.1186/s12931-021-01777-x.
4. Zheng Y, Zhu J, Liu Y, Lai W, Lin C, Qiu K, et al. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ (Clinical Research Ed) 2018;363:k4388. https://doi.org/10.1136/bmj.k4388.
5. van den Berge M, De Backer J, Van Holsbeke C, De Backer W, Trivedi R, Jenkins M, et al. Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids. Respiratory Research 2021;22:1–12. https://doi.org/10.1186/s12931-021-01772-2.
6. Ohtsuka K, Harada N, Horiuchi A, Umemoto S, Kurabatashi R, Yui A, et al. Therapeutic Response to Single-Inhaler Triple Therapies in Moderate-to-Severe COPD. Respiratory Care 2023;68:330–7. https://doi.org/10.4187/respcare.10188.
7. Crane K, Zappetti D. How Does the Efficacy and Safety of Triple Inhaled Therapy at 2 Glucocorticoid Doses Compare With 2 Dual Therapies in Moderate- to-Very-Severe COPD? Clinical Pulmonary Medicine 2020;27:157–9. https://doi.org/10.1097/CPM.0000000000000378.
8. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. New England Journal of Medicine 2020;383:35–48. https://doi.org/10.1056/nejmoa1916046.
9. Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled tr. The Lancet Respiratory Medicine 2018;6:747–58. https://doi.org/10.1016/S2213-2600(18)30327-8.
10. Wang C, Yang T, Kang J, Chen R, Zhao L, He H, et al. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS. Advances in Therapy 2020;37:1591–607. https:// doi.org/10.1007/s12325-020-01266-5.